Search

Your search keyword '"Olbrich, H"' showing total 222 results

Search Constraints

Start Over You searched for: Author "Olbrich, H" Remove constraint Author: "Olbrich, H" Language english Remove constraint Language: english
222 results on '"Olbrich, H"'

Search Results

1. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

2. Long-Term Effect of Endothelin Receptor Antagonism With Bosentan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the ENABLE Trials

3. Mutations in CCNO and MCIDAS lead to a mucociliary clearance disorder due to reduced generation of multiple motile cilia

4. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study

11. Ezetimibe added to statin therapy after acute coronary syndromes

15. Psychobiological responses to drug cues before and after methadone intake in heroin-dependent patients: a pilot study

16. Loss of nephrocystin-3 function can cause embryonic lethality, Meckel-Gruber-like syndrome, situs inversus, and renal-hepatic-pancreatic dysplasia

17. The Right of the Employee to Refuse to be Transferred. A comparative and theoretical analysis

22. Mutations of DNAI1 in primary ciliary dyskinesia: evidence of founder effect in a common mutation.

23. DNAH5 mutations are a common cause of primary ciliary dyskinesia with outer dynein arm defects.

27. Endothelium-dependent and endothelium-independent vasomotion in large coronary arteries and in the microcirculation after cardiac transplantation.

29. Calcium overload in human giant cell myocarditis.

31. Further Evidence for a Somatic KRAS Mutation in a Pilocytic Astrocytoma.

37. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

42. Large-scale analysis highlights obesity as a risk factor for chronic, non-communicable inflammatory diseases.

43. Biological, as opposed to classic antipsoriatic drug or apremilast, treatment mitigates the risk of death and cardiovascular disease in psoriasis.

44. Pathogenic KIAA0586/TALPID3 variants are associated with defects in primary and motile cilia.

45. Mortality in adult patients with chronic spontaneous urticaria: A real-world cohort study.

46. Pathogenic variants in CFAP46 , CFAP54 , CFAP74 and CFAP221 cause primary ciliary dyskinesia with a defective C1d projection of the central apparatus.

48. Comparison of safety profile in patients with atopic dermatitis treated with dupilumab or conventional systemic treatment: real world data from the US network.

49. Atopic dermatitis is associated with an increased risk of cardiovascular diseases: a large-scale, propensity-score matched US-based retrospective study.

50. A range of 30-62% of functioning multiciliated airway cells is sufficient to maintain ciliary airway clearance.

Catalog

Books, media, physical & digital resources